Ralliant Corporation (NYSE:RAL) Receives Average Recommendation of “Moderate Buy” from Analysts

Ralliant Corporation (NYSE:RAL) has been given an average recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $73.00.

RAL has been the topic of several research reports. Barclays upped their price target on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Zacks Research raised Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. BMO Capital Markets began coverage on Ralliant in a report on Monday. They issued a “market perform” rating and a $78.00 target price on the stock. Citigroup boosted their target price on Ralliant from $70.00 to $81.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Truist Financial reaffirmed a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in RAL. Danske Bank A S purchased a new position in shares of Ralliant in the fourth quarter worth approximately $25,000. Allworth Financial LP lifted its position in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of Ralliant in the 4th quarter valued at approximately $26,000. Palisade Asset Management LLC purchased a new stake in shares of Ralliant in the 3rd quarter valued at approximately $26,000. Finally, Versant Capital Management Inc boosted its stake in Ralliant by 230.1% in the 2nd quarter. Versant Capital Management Inc now owns 604 shares of the company’s stock worth $44,000 after purchasing an additional 421 shares during the period.

Ralliant Stock Performance

NYSE:RAL opened at $69.55 on Friday. The company has a 50-day moving average of $66.43 and a 200-day moving average of $53.80. The firm has a market cap of $7.78 billion and a price-to-earnings ratio of -6.36. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. Ralliant has a twelve month low of $37.27 and a twelve month high of $75.41.

Ralliant (NYSE:RAL) last released its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business had revenue of $534.60 million for the quarter. The company’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Analysts forecast that Ralliant will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s payout ratio is presently -1.83%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.